Paloma Wang

Ms. Wang is listed as a Notable Practitioner for Equity Capital Markets by IFLR1000 2020. She also was previously noted for her “distinguished leadership” by The Legal 500 Asia Pacific.

Ms. Wang’s experience (including prior to joining Skadden) includes advising:

• JD.com, Inc. in its US$4.27 billion secondary listing of new ordinary shares on the Hong Kong Stock Exchange. This was the largest global offering on the Hong Kong Stock Exchange in 2020, and the second-largest globally;
• JD Health International Inc. in its US$3.47 billion initial public offering and listing on the Hong Kong Stock Exchange. This is the largest IPO in Hong Kong in 2020 and the second-largest listing, with the largest being parent company JD.com’s secondary listing;
• NetEase, Inc. in its US$3.1 billion secondary listing of new ordinary shares on the Hong Kong Stock Exchange;
• New Oriental Education & Technology Group Inc. in its US$1.3 billion secondary listing of new ordinary shares on the Hong Kong Stock Exchange;
• ZTO Express (Cayman) Inc. in its US$1.25 billion secondary listing of Class A ordinary shares on the Hong Kong Stock Exchange;
• Yidu Technology Inc. in its US$531 million initial public offering and listing on the Hong Kong Stock Exchange; 
• Everest Medicines in its US$451 million initial public offering and listing on the Hong Kong Stock Exchange;
• JHBP (CY) Holdings Limited (Genor Biopharma) in its US$371 million initial public offering and listing on the Hong Kong Stock Exchange;
• HBM Holdings Limited (Harbour BioMed) in its US$221 million initial public offering on the Hong Kong Stock Exchange;
• Neusoft Education in its US$134 million initial public offering and listing on the Hong Kong Stock Exchange;
• Cathay Media and Education Group in its US$183 million initial public offering on the Hong Kong Stock Exchange;
• InnoCare Pharma Limited in its US$314 million initial public offering on the Hong Kong Stock Exchange (representing the underwriters);
• Innovent Biologics, Inc. in its:
  • US$421 million global offering and listing on the Hong Kong Stock Exchange;
  • US$300 million top-up issuance;
  • US$304 million placing of new shares under the general mandate; and
  • US$363 million placing of new shares and concurrent $267 million sale of existing shares;
• Pharmaron Beijing Co., Ltd. in its US$683 million initial public offering of H shares and listing on the Hong Kong Stock Exchange (representing the underwriters);
• China YuHua Education Corporation Limited in its HK$940 million Regulation S offering of 3.00% convertible bonds due 2020. The bonds were listed on the Hong Kong Stock Exchange;
• Koolearn Technology Holding Limited (China) in its:
  • US$246 million initial public offering and listing on the Hong Kong Stock Exchange; and
  • acquisition of the remaining 49% equity interest in Dongfang Youbo for RMB 94 million (US$13.4 million);
• CStone Pharmaceuticals in its US$285 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters);
• Tianli Education International Holdings Limited in its initial public offering in Hong Kong;
• China Renaissance Holdings Limited in its US$350 million initial public offering and listing on the Hong Kong Stock Exchange;
• WuXi Biologics (Cayman) Inc. and G&C VII Limited in their respective capacities as the issuer and controlling shareholder on the approximately US$600 million placing of new shares and existing shares;
• WuXi Biologics Holdings Limited in the sale of its existing shares of WuXi Biologics (Cayman) Inc. for a consideration of approximately US$650 million;
• WuXi Biologics (Cayman) Inc. in its US$510 million global offering and initial public offering on the Hong Kong Stock Exchange (representing the underwriters);
• Haihe Biopharma (Cayman) Limited, a developer of tumor-related drugs, on its US$146.6 million Series A financing led by Huagai Capital;
• Future Land Development Holdings Limited in its:
  • approximately US$265 million global offering and initial public offering on the Hong Kong Stock Exchange; and
  • approximately US$200 million top-up share placing and issuance of approximately US$300 million convertible notes;
• Sinco Pharmaceuticals Holdings Limited in its global offering and initial public offering on the Hong Kong Stock Exchange;
• CGN Power Co. Ltd., China’s largest nuclear power producer, in its US$3.2 billion global offering and initial public offering on the Hong Kong Stock Exchange;
• Danone Asia Pte. Ltd. in its sale of Dumex Baby Food Co., Ltd. to Yashili International Holdings Limited and investment in China Mengniu Dairy Company Limited;
• Midas Holdings Limited, a Singapore-incorporated company, in its approximately US$150 million secondary listing on the Hong Kong Stock Exchange;
• Besunyen Holdings Company Limited in its HK$1.3 billion global offering and initial public offering of on the Hong Kong Stock Exchange (representing the underwriters);
• China Animal Healthcare Ltd. in its listing by way of introduction of on the Hong Kong Stock Exchange (representing the underwriters);
• Dali Foods Group Company Limited in its US$1.15 billion global offering and initial public offering of on the Hong Kong Stock Exchange (representing the underwriters);
• Guorui Properties Limited in its US$203 million global offering and initial public offering of on the Hong Kong Stock Exchange (representing the underwriters);
• China Machinery Engineering Corporation in its US$500 million global offering and initial public offering of H shares of on the Hong Kong Stock Exchange (representing the underwriters); and
• Tianjin Port Development Limited in its US$135 million global offering and initial public offering through a spin-off from Tianjin Development (representing the underwriters).

Ms. Wang joined Skadden in 2018 and prior to that worked in the Hong Kong office of another highly regarded global law firm as a partner in its capital markets practice. Ms. Wang speaks fluent English, Mandarin and Cantonese.